KRAS and pancreatic neoplasm: Despite the limitations, the case report highlights the potential efficacy of TCR gene therapy in targeting the KRAS G12D hot-spot mutation and inducing regression of metastatic pancreatic cancer, and therefore provides an important basis for future studies.